Abstract. Knowledge of the circadian patterns of serum IGF-I I and the large molecular weight IGF binding protein, IGFBP-3 might, apart from its physiological relevance, be of clinical interest, inasmuch as measurements of these parameters are being introduced into the evaluation of GH deficiency. We therefore evaluated the 24-h (08.00-08.00 h) patterns of serum IGF-II and IGFBP-3 in 8 GH-deficient patients who were studied during three periods when receiving 1. GH (2 IU) at 20 .00 h; 2. GH (2 IU) at 08.00 h and 3. no GH. For comparison, 10 age-and sex-matched untreated healthy subjects were studied once under similar conditions. The serum IGF-II levels of the patients were relatively stable over the 24-h periods, yielding mean levels which were significantly lower during no GH: 553\m=+-\78(evening GH), 554\m=+-\54(morning GH), and 429\m=+-\65 \ g=m\ g/ l (no GH). The mean IGF-II level in the normal subjects was 635\m=+-\29 \g=m\g/l , which was significantly higher than in either patient study. (9) (10) (11) (12) (13) (14) . Accord¬ ing to a recent suggestion (15) , they are now de¬ signated IGFBP-1, IGFBP-2, IGFBP-3 and CSF-IGFBP, the latter a binding protein isolated from cerebrospinal fluid (14) . IGFBP-1 exhibits distinct diurnal fluctuations, which seem to be GH-independent but rather influenced by nutritional vari¬ ables (16) (17) (18) . So (19) . It is GH-dependent with low levels in GH deficiency and high levels in acromegaly (20, 21) and is presumed to function as a re¬ servoir and buffer for IGFs (22) . It 
Subjects and Methods
Eight GH-deficient patients participated: 2 females and 6 males, mean chronologic age 15.3 years (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Although the 24-h patterns appeared stable as also reflected by the average CVs between 6.9-7.8%, a significant variation with time of this parameter was observed in all patient studies, the most con¬ sistent finding being a decline in the night. The mean levels in the patients during GH therapy were 2755+317 (evening GH) and 2904+269 pg/1 (morning GH) (NS), respectively. The mean level during no GH therapy was 1853+301 pg/1, which was significantly lower than in both GH treatment modes (p<0.01).
A mild but significant change over time of serum IGFBP-3 was also recorded in the normal subjects, again in spite of an average CV over the 24 h of only 6.3%. The mean level was 3856+186 pg/1, which was significantly higher than in either of the patient studies (p<0.001).
A positive correlation between the mean values at each time point of IGF-II and IGFBP-3 was ob¬ served in all studies and reached statistical signifi¬ cance except in the study where the patients did not receive GH.
Discussion
This study is the first to examine the circadian levels of serum IGF-II and IGFBP-3 in GH-defi¬ cient patients using highly specific RIAs (8, 21) . No gross circadian fluctuations were observed, al¬ though a small but significant change over time of both parameters was recorded in some of the stud¬ ies, the consistent finding being a minor decline during night. The 24-h mean level of IGF-II during GH treat¬ ment was significantly lower than in the normal subjects. This is in agreement with our previous experience with serum IGF-I using the same daily GH dose (in average 1.5 IU/m2 body surface) (24, 25 the control group also seemed higher than previ¬ ously experienced (8) . On the other hand, mean values above 400 pg/1 in relatively large groups of GH-deficient patients have been reported in stud¬ ies by other investigators (26, 27) . In these studies as well as in ours there was a trend towards somewhat higher levels in pubertal subjects (26) and in pa¬ tients with craniopharyngeoma (27) . At 
